The proteinopenia hypothesis: Loss of Aβ42 and the onset of Alzheimer’s Disease
Alberto J. Espay, Karl Herrup, Kasper P. Kepp, Timothy Daly
Abstract
The dominant protein-lowering strategy in Alzheimer's Disease (AD) has failed to provide a clinically-meaningful treatment for patients. We hypothesize that the loss of functional, soluble Aβ42 during the process of aggregation into amyloid is more detrimental to the brain than the corresponding accrual of insoluble amyloid.
Topics & Concepts
DiseaseAmyloid (mycology)NeuroscienceAlzheimer's diseaseAmyloid βMedicinePsychologyInternal medicinePathologyAlzheimer's disease research and treatmentsPrion Diseases and Protein MisfoldingComputational Drug Discovery Methods